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SuMMAry – The worldwide incidence of differentiated thyroid cancer (dTC) has increased in 
recent decades, likely due to frequent use of cervical ultrasonography (uS) and uS-guided fine needle 
aspiration biopsy (fnA)., uS is performed during follow-up after thyroidectomy, and uS-guided 
fnA with cytology is used if suspicious cervical lymph nodes (ln) or thyroid bed masses are de-
tected. knowing that serum anti-Tg antibodies (sTgAb) affect the use of serum Tg (sTg) as a tumor 
marker, the aim of our study was to assess the usefulness of Tg determination in needle aspirates 
(fnA-Tg) in presence of sTgAb. This retrospective study included 149 patients with dTC and 159 
aspirations of suspicious ln and thyroid bed masses. As expected, there was a negative correlation 
between sTg and sTgAb levels (p<0.05), while fnA-Tg levels had a positive correlation with fnA-
TgAb levels (p<0.05). furthermore, we found a positive correlation between sTg and fnA-Tg levels 
(p<0.05), but not between sTgAb and fnA-TgAb or sTgAb and fnA-Tg. in conclusion, these re-
sults show that fnA-Tg values were not affected by sTgAb and that fnA-Tg measurement were 
highly effective in detecting cervical dTC metastases. however, combined use with cytology is sug-
gested for neck evaluation because cytology could reveal metastases from other tumor sites. 
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Introduction
The worldwide incidence of thyroid cancer has in-
creased several times in recent decades (1). Croatia is 
currently the third country in europe due to an inci-
dence rate of 15.9 per 100.000 in 2016, whereas mor-
tality has steadily declined (2,3). This change is most 
likely due to the increased use of cervical ultrasonogra-
phy (uS) and uS-guided fine needle aspiration biopsy 
(fnA). Patients with differentiated thyroid cancer 
(dTC) have a good prognosis, but since the imple-
mentation of a long-term follow-up monitoring scheme 
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it has become clear that up to a third of patients pres-
ent with persistent disease or recurrences (4). recent 
studies demonstrated that patients with dTC have the 
highest incidence of local recurrences within the first 5 
years (5). The risk of recurrences ranges from 2% to 
14%, in case of excellent response to therapy, while an 
incomplete response to initial therapy (suppressed Tg 
>1 ng/ml, stimulated Tg >10 ng/ml, rising Tg values, 
or structural disease identification within the first 2 
years of follow-up) increases the likelihood of persis-
tent structural disease or recurrence from 13% to 79% 
in high-risk patients (6). Therefore, the risk of recur-
rence is associated with initial risk stratification based 
on clinico-pathologic features, but the estimated re-
currence risk needs to be continually modified during 
follow-up, since it can change in response to therapy 
(6-8). locoregional metastases are most often located 
in the cervical lymph nodes (ln) (60-75%), and in the 
thyroid bed (20%), with a diameter frequently under 1 
cm (29-50%) (9,10). follow-up of these patients after 
total thyroidectomy and radioiodine ablation of the 
thyroid remnant is mostly based on cervical uS, serum 
thyroglobulin (sTg) measurement, and thyroptropin 
(TSh) measurement. Additional methods include 
SPeCT/CT, bone scintigraphy, chest X-ray, CT, Mr, 
or PeT-CT, which should be used when necessary.
Cervical uS is considered to be the best modality 
for the early detection of locoregional recurrences and 
thyroid bed recurrences of dTC in patients after thy-
roidectomy (11-13). The majority of recurrences are 
rarely palpable but are detected by uS in 94-96% of 
cases (9). uS-guided fnA with cytology is performed 
when suspicious cervical masses are detected. Tg mea-
surement in fine needle aspirates was introduced in 
1992 (14). uS-guided fnA with cytology should be 
performed simultaneously with the measurement of 
Tg in needle aspirates (fnA-Tg) of suspicious nodes 
to confirm malignancy (11,15-17). Published data 
suggested that cytology alone was indicative of malig-
nancy in 84.8%, whereas cytology together with fnA-
Tg measurement was accurate in 95.6% patients (9). 
uS characteristics of a suspicious mass in the thyroid 
bed include hypoechogenicity, microcalcifications, cys-
tic changes, irregular borders, and increased intranodal 
vascularity. Sonographic features essential in evalua-
tion of metastatic ln include loss of the fatty hilus, a 
rounded rather than oval shape, hypoechogenicity, cys-
tic change, calcifications, and peripheral vascularity. 
with regard to location location, malignant ln are 
much more likely to occur in levels Vi, iV, and iii than 
in level ii. Cervical uS can detect metastases as small 
as 2-3 mm, but benefits of early discovery have not 
been demonstrated (8). Small (short axis <5-7 mm) 
cervical lns in the lateral neck can remain stable dur-
ing long periods of time and should just be regularly 
followed with serial uS. That being said, it has been 
proposed to perform uS guided fnA and Tg mea-
surement for suspicious lns >5-7 mm in its smallest 
diameter and thyroid bed lesions ≥10 mm (8,11.)
Measurement of sTg is a sensitive and specific tu-
mor marker for follow-up of patients with dTC after 
surgical removal of the thyroid gland and ablation of 
the remnant tissue (18,19), with high degree of sensi-
tivity and specificity in detecting recurrent disease and 
ln metastases. immunochemistry assays are used to 
measure sTg in most laboratories. These assays are 
prone to interference from serum Tg autoantibodies 
(sTgAb), which are present in about 25% of patients 
and can falsely lower sTg values (20). The level of in-
terference can be dependent on the methodology used 
for analyzing Tg and TgAb, with newer immunoassay 
techniques being less prone to false negative results. 
regardless, TgAb should be always quantitatively as-
sessed with measurement of sTg (21). Confirmed in-
terference of sTgAb on sTg has raised potential con-
cerns about using fnA-Tg result,s in presence of 
sTgAb. in 2013 boi et al. (22) presented results show-
ing no significant correlation between sTgAb and 
fnA-Tg values. in comparison, Jeon et al. (23), stated 
that fnA-Tg measurement was reliable in the diagno-
sis of neck metastases in PTC, even in cases with pos-
itive sTgAb, but high sTgAb levels could interfere 
with fnA-Tg measurements resulting in falsely low 
fnA-Tg levels.
The aim of our study was to assess the usefulness of 
fnA-Tg in the presence of sTgAb, while considering 
the possibility of ln contamination by sTgAb and al-
ternatively active ln TgAb synthesis.
Methods
This retrospective study included 149 patients (101 
women and 48 men) with dTC, with ages ranging 
from 12 to 86 years. All subjects were Caucasians of 
Croatian origin. The medical records of patients were 
obtained from 2014 to 2016 at the Sestre milosrdnice 
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Clinical hospital Centre (Zagreb, Croatia) and re-
viewed retrospectively. All patients had received total 
thyroidectomy. Thyroxin therapy had been adminis-
tered to patients after i-131 therapy. Patients were fol-
lowed up by cervical uS, sTg, and sTgAb determina-
tion and i-131 scintigraphy when necessary. when 
necessary, chest X-ray, bone scintigraphy, CT, Mr, or 
PeT-CT were performed. All procedures were in ac-
cordance with good clinical practice and with the hel-
sinki declaration of 1975, as revised in 1983.
Clinical measurements
Cervical uS was performed with “Xario” Toshiba 
using a linear 7-12 Mhz probe and small convex 7 
Mhz probe for the evaluation of the upper mediasti-
num and for uS-guided fnA. uS of the thyroid bed 
and entire neck, including lateral cervical compart-
ments and upper mediastinum, was performed. Color 
flow and power doppler examination was included. 
uS characterization of a suspicious mass in the thyroid 
bed included assessment of hypoechogenicity, micro-
calcifications, cystic changes, and increased intranodal 
vascularity. uS features suggestive of metastatic ln 
included loss of the fatty hilus, a rounded rather than 
oval shape, hypoechogenicity, cystic change, calcifica-
tions, and peripheral vascularity. The location of the 
ln was also useful for decision-making. Malignant 
ln were much more likely to occur in levels Vi, iV, 
and iii than in level ii.
uS-guided fnA with cytology and fnA-Tg was 
obtained from uS-suspicious neck masses. A 23-24 
--gauge needle with parallel approach was used for 
uS-guided fnA. uS guidance and free hand tech-
nique was employed. A specimen for cytology was ob-
tained by applying suction. The cytological specimen 
was prepared by making a slide smear and stained with 
May-grünwald-giemsa. The fnA cytology results 
were categorized as nonmalignant (reactive ln, some 
other benign disease), malignant cytology (metastatic 
dTC), or inadequate (cystic fluid, not enough cells for 
analysis). After smear preparation, the same needle 
and syringe were rinsed with 0.5 ml MultiAssay di-
luent (roche) to assess Tg in samples. This procedure 
does not require additional fnA. Tg was measured in 
washout fluid (fnA-Tg). when the aspiration sam-
ples were serous fluid, Tg was measured in the serous 
fluid without adding diluent. All smears were exam-
ined by the same cytologist.
Serum Tg was determined using the Cobas e411 
(roche diagnostics, Mannheim, germany) automat-
ed immunochemistry analyzer using electroChemi-
luminescence (eCl) technology with an analytical 
sensitivity threshold of 0.04 ng/ml and a functional 
sensitivity threshold of 0.1 ng/ml. immunoassay was 
calibrated against the CrM-457 international stan-
dard. Tg in all aspirates (fnA-Tg) was measured with 
the same assay. Tg measurement in needle washout or 
cystic samples was performed using the same method 
as for sTg. in all patients, Tg-Ab was measured using 
the Cobas e411 (roche diagnostics, Mannheim, ger-
many) automated immunochemistry analyzer using 
electroChemiluminescence (eCl) technology with 
the analytical sensitivity <10 iu/ml and a functional 
sensitivity threshold of 40 iu/ml; antibody positivity 
was defined as a TgAb value exceeding 115 iu/ml.
Serum Tg, TgAb, and TSh were measured within 
a few weeks before the uS-guided fnA procedure.
The suspected lns or suspected cervical tissue 
were categorized as benign or malignant. relevant di-
agnostic procedures for confirming or excluding diag-
nosis were histology results from subsequent surgical 
excisions or fnA cytology results and/or fnA-Tg 
results and long-term uS follow-up without changes 
in size if the surgery was not performed. Positive diag-
nosis was established if there was histological confir-
mation of metastasis or clear uS evidence of metasta-
sis with malignant cytology and/or fnA-Tg results. 
negative diagnosis was established for those ln or 
masses with negative histology, cytology, and/or fnA-
Tg results.
Statistical analysis
Clinical data was reported using descriptive statis-
tics. The results, expressed as means (x) ± standard de-
viation (Sd) or medians, were evaluated with Statistica 
10 Software. The correlation of data was evaluated us-
ing Spearman’s correlation coefficient. The differences 
in the frequencies were evaluated using the Chi-square 




in total, 149 patients were included in this study, 
101 (67.79%) women and 48 (32.21%) men. Their me-
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dian age was 48 years (ranging from 12 to 86 years). 
Cervical uS revealed 159 cervical lns or masses in 
the thyroid bed suspected for malignancy. uS-guided 
fnA with cytology was performed in all suspicious 
nodes. STg and sTgAb were determined in all 149 pa-
tients with uS findings indicative for malignancy. 
fnA-Tg and Tg antibodies were determined in all 
washouts or cystic samples.
The patients were divided into two groups accord-
ing to their sTgAb values (figure 1). There were 31 
(20.81%) patients with positive sTgAb values and 118 
(79.19%) patients with negative sTgAb values.
descriptive statistics of patients divided into two 
groups according to their sTgAb levels is presented in 
Table 1. in 31 patients with positive sTgAb, cervical 
uS revealed 34 suspicious nodes. elevated fnA-Tg 
values were found in 11 patients and 13 samples, con-
firming locoregional malignancies. Among patients 
with positive fnA Tg values, there was a large dis-
crepancy in fnA Tg Ab values. namely, two patients 
had fnA TgAb values above 450 while the remaining 
11 had values below 115. in 10 of those samples with 
low fnA-TgAb, cytology was positive and was false 
negative in 1 sample. fnA-Tg values ranged from 
1.26 ng/ml to >500 ng/ml. in the remaining two 
samples, fnA-Tg values were elevated to >500 ng/
ml, accompanied by high fnA-TgAb values, while 
cytology revealed malignancy in both samples without 
false negative results. Of those 31 patients with posi-
tive sTgAb, 20 had negative fnA-Tg with negative 
cytology findings for malignancy in 19 of those pa-
tients and nondiagnostic in one.
from a total of 118 patients with negative sTgAb 
and 125 nodes suspected for malignancy, 33 samples 
from 32 patients had elevated fnA-Tg values ranging 
from 1.62 to >500 ng/ml. in 19 of those, fnA-Tg 
positive cytology findings were positive for malignan-
cy, 3 were suspicious for malignancy, 7 samples were 
negative for malignancy, and 4 samples were not suit-
able for diagnostics.
in total, 46 samples were positive for locoregional 
metastases of thyroid cancer or thyroid bed recurrenc-
es. Out of 46 samples with elevated fnA-Tg values, 
34 had cytology findings positive or suspicious for thy-
roid malignancy, while 12 were negative on cytology 
for dTC. from those 12, 7 were in fact residual thy-
roid tissue and 5 were false negative. Cytology was 
positive for metastases of mucinous adenocarcinoma 
in one patient with undetectable fnA-Tg.





Patients/suspicious nodes 31/34 118/125
Age-median (years) 43 (26-86) 51 (12-85)
s-Tg-median (ng/ml) 0.14 0.79


















Figure 1. The patients were divided into two groups 
according to their sTgAb (IU/mL) levels.
Correlation statistics
Our results revealed a significant inverse correla-
tion of sTg levels with sTgAb levels (Spearman’s rho=-
0.275, p<0.05) (figure 1). On the other hand, our re-
sults showed a significant positive correlation of fnA-
Tg values with fnA-TgAb levels (Spearman’s rho= 
0.514, p<0,05) (figure 2). fnA TgAb values are not a 
commonly measured value and there is no accepted 
cutoff value. but if we consider a cutoff value of 115 for 
serum TgAb, then there is a significant difference 
in the distribution of fnA-Tg values (chi 44.13, 
p<0.0001) among the groups of patients with fnA-
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TgAb values of over and under 115. in the group of 
patients with higher fnA-TgAb values, almost all had 
positive fnA-Tg values (17/18), while the proportion 
of patients with positive fnA-Tg was low among pa-
tients with low fnA-TgAb values (29/141). 
furthermore, there was also a significant positive 
correlation between sTg and fnA-Tg levels (Spear-
man’s rho=0.277, p<0.05). The majority (63.64%) of 
patients with fnA-Tg-positive values had also posi-
tive s-Tg values and vice versa (Chi 8.87, p<0.004).
On the other hand, our results have shown that 
there was no correlation between sTgAb and fnA-
TgAb (Spearman’s rho=0.118, p>0.05), or between 
sTgAb and fnA-Tg (Spearman’s rho=-0.013, p>0.05). 
Discussion
long-term follow-up of patients with dTC after 
total thyroidectomy should include appropriate meth-
ods for detecting possible recurrences. Patients with 
higher risk of recurrence should undergo follow-up 
examinations more frequently than the patients un-
likely to develop relapse of disease. Measurement of 
sTg, cervical uS, and occasionally whole-body scintig-
raphy are commonly used in the detection of metasta-
ses in patients with dTC (8,24).
The measurement of sTg levels is an important 
modality included in follow-up of patients after a total 
thyroidectomy for dTC and radioiodine ablation of 
the remnant tissue (18,25). sTg has a high degree of 
sensitivity and specificity for the detection of a recur-
rent disease. The highest sensitivity is achieved follow-
ing thyroid hormone withdrawal or stimulation using 
recombinant TSh (20). it is known that 1 gram of 
neoplastic tissue will increase sTg values by approxi-
mately 1 µg/l during levothyroxine treatment and by 
2-10 µg/l following TSh stimulation (26,27). Pa-
tients considered disease free should have sTg <0.2 ng/
ml while on thyroid hormone therapy or sTg <1 ng/
ml after TSh stimulation (8). however, sTg mea-
surement obtained during thyroid hormone suppres-
sion of TSh, and less commonly during TSh stimula-
tion, may fail to detect patients with a relatively small 
amount of tumor tissue which are usually related to 
locoregional metastases (12,28). Another drawback of 
this method is that sTg assays are prone to interfer-
ence with sTgAb, which are present in about 25% of 
patients and falsely lower sTg values (20,21). Our re-
sults also demonstrated a negative correlation between 
sTg and sTgAb values, although our automatic im-
munoassay method is more advanced than those cited, 
with less possible interference in sTg and sTgAb de-
tection.
Cervical uS is a sensitive, but not specific tool for 
detection of locoregional recurrences (29,30). uS-
guided fnA with cytology of suspicious nodes is per-
formed to confirm malignancy. however, fnA sam-
ples potentially have low cellularity that is lacking 
characteristic cytological features of thyroid cancer 
(31). Additionally, cystic changes in metastatic ln 
may be another diagnostic pitfall in fnA cytology. 
determination of Tg in samples was introduced to 
overcome these disadvantages (14). A number of stud-
ies showed that fnA-Tg improves the sensitivity of 
cytology for the identifications of metastatic ln and 
thyroid bed recurrences (9,11,16,21,23,32-35). Mea-
surement of fnA-Tg enhances the sensitivity of cy-
tology in up to 20% of aspirates (33,36). furthermore, 
it is important to point out the fact that the neck re-
gion is involved in a variety of extrathyroidal malig-
nancies and that metastases of other cancer can poten-
tially be detected by cytology in this region. That being 
said, we found that one patient suspected of dTC 
with undetectable fnA-Tg had a cytology result posi-
tive for metastases of mucinous adenocarcinoma. Most 
of the studies reported that diagnostic accuracy of 
fnA-Tg in the detection of neck malignancies is 
highly reliable even in cases with negative stimulated 
serum Tg (20,32,37). furthermore, there is the ques-
Figure 2. Correlation between FNA TgAb (IU/mL)  
and FNA Tg (ng/mL).
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tion of fnA-Tg cutoff which varies between studies. 
The most used cutoff values are: fnA-Tg <1 ng/ml 
suggests a benign nodule, while values of Tg >10 ng/
ml suggest presence of malignancy. when fnA-Tg 
measures are between 1 ng/ml and 10 ng/ml, results 
should be compared with serum Tg (11). A more re-
cent study suggested a value of 1.0 ng/ml fnA-Tg as 
a cutoff for diagnosing metastasis of papillary cancer 
(15,38), which we also used in this study. borel et al. 
described that low fnA Tg values below 10 ng/fnA 
can indicate dTC metastasis without a correlation to 
serum Tg, even when expressed as total Tg left in nee-
dle after aspiration and not as concentration after 
washout. On the other hand, our results showed a sig-
nificant positive correlation between sTg and fnA-
Tg levels.
while it is known that serum TgAb interferes with 
serum Tg measurement, producing underestimation of 
Tg concentration, some previous studies have shown 
that fnA-Tg measurement is valid in patients with 
circulating serum Tg-Ab (9,16,20,32,34,37,39). A 
possible explanation was that intracellular Tg was not 
exposed to circulating sTgAb, but these results have 
not been confirmed in all studies (16). Jeon et al. re-
ported in 2013 that ln metastases presented with 
lower fnA-Tg values in patientswho were sTgAb 
positive than in patients without sTgAb, suggesting 
that high sTgAb levels could interfere with fnA-Tg 
measurements and thereby result in falsely low fnA-
Tg levels (23). in comparison, in his more recent study 
Jeon described that preoperative fnA-Tg levels were 
not related to TSh or sTgAb (40). furthermore, a 
study by Jo et al. suggested lower diagnostic accuracy 
of fnA-Tg in patients with positive sTgAb, but just 
in preoperative cases (41), while Shin et al. reported a 
possible effect of sTgAb on fnA-Tg cutoff values 
(42). On the other hand, duval et al. reported no dif-
ference between fnA-Tg cutoff values in relation to 
sTgAb (43). it is very important to mention that these 
studies did not perform fnA-TgAb measurements as 
we have in our study. fnA-TgAb measurement is not 
a routinely used method, and it is important to empha-
size that cut-off values for fnA-TgAb have not been 
determined. The question is what we can classify as a 
positive fnA-TgAb value. if we hypothetically take 
the same cutoff as for the 115 iu/ml serum sTgAb, 
our results show a strong correlation of fnA-Tg val-
ues with fnA-TgAb levels as confirmed by Spearman 
correlation analysis, but further research is needed to 
set the actual cutoff for fnA-TgAb. in addition to 
these results, we demonstrated no statistically signifi-
cant direct correlation between serum TgAb and 
fnA-Tg.
Our assumption that serum TgAb affects fnA-Tg 
implies that serum TgAb can affect fnA-TgAb. Al-
ternatively, there is a possibility of metastatic ln ac-
tive TgAb synthesis as proposed in 1984 (44). in this 
study, we demonstrated that there was no correlation 
between serum TgAb and fnA-TgAb values. based 
on these results, we concluded that there can be no ef-
fect of TgAb on fnA-Tg except from potentially ac-
tive metastatic ln TgAb synthesis. in that regard, we 
demonstrated a positive correlation between fnA-
TgAb and fnA-Tg in both serum TgAb positive and 
negative patients, thus excluding the negative effect of 
fnA-TgAb on fnA-Tg values by active fnA-TgAb 
synthesis in ln.
The limitations of statistical analysis consisted in 
significantly elevated values of Tg in certain samples 
because no further sample dilution was performed. 
high fnA-Tg values over 2000 ng/ml can lead to 
false-elevated fnA-TgAb (39,45). The limitation of 
our study design was that we did not have enough his-
tological data for further comparison with cytology 
and fnA-Tg results. The reason for this was that our 
patients with smaller locoregional metastases were not 
sent for surgical removal until significant enlargement, 
which rarely occurred. when confirmation of malig-
nancy was achieved by uS-guided fnA with cytology 
and/or measurement of fnA-Tg, the preferred initial 
treatment was surgical removal of primary tumor and 
locoregional metastases (46,47). while the resection 
of large, clinically apparent recurrences and locore-
gional metastases often provides a clinical benefit, it is 
uncertain whether the resection of small locoregional 
recurrence has any meaningful clinical impact. Small 
cervical ln metastases and thyroid bed recurrences 
can remain stable for longer periods of time and their 
significance is unclear (8,10,28).
Combined use of uS and uS-guided fnA with 
cytology and fnA-Tg measurement are indicated for 
neck evaluation because of enhanced sensitivity for 
dTC, while metastases from other tumors could also 
be revealed by cytology findings. uS-guided fnA per-
formed to obtain both cytology samples and Tg deter-
mination is considered the best available technique for 
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the early diagnosis of locoregional metastases. Our 
study indicates that determination of elevated Tg lev-
els in fine needle samples is effective in detection of 
cervical ln metastases and/or recurrences even in 
cases were cytology is nondiagnostic or negative and 
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Sažetak
OdreĐiVAnJe  VriJednOSTi TireOglObulinA u CiTOlOŠkOM ASPirATu  
u SVrhu OTkriVAnJA reCidiVA i MeTASTAZA nA VrATu u bOleSnikA  
S diferenCirAniM kArCinOMOM ŠTiTnJAČe: ZnAČAJ AnTi-Tg PrOTuTiJelA
I. Blažeković, M. Romić, M. Bosak Butković, I. Šiško Markoš, V. Gladić Nenadić, V. Vidranski,  
P. Petranović Ovčariček, D. Krilić, T. Varjačić, J. Staničić, R. Granić, M. Punda, I. Mihaljević, T. Jukić i M. Franceschi
Svjetska incidencija diferenciranog karcinoma štitnjače (dTC) u porastu je posljednjih desetljeća najvjerojatnije zbog 
povećane uporabe ultrazvuka (uS) i uS vođene aspiracijske biopsije tankom iglom (fnA). nakon provedene tireoidekto-
mije, onkološko praćenje uključuje uS i uS vođenu fnA i citološku analizu aspirata ukoliko se otkriju sumnjivi cervikalni 
limfni čvorovi (ln) ili tkivo u ležištu štitnjače. kako je poznato da serumska protutijela na tireoglobulin (sTgAb) utječu na 
vrijednost serumskog Tg (sTg) kao tumorskog markera, cilj našeg istraživanja je procijeniti korisnost određivanja Tg u aspi-
ratima suspektnih lezija (fnA-Tg) u prisutnosti sTgAb. Ova retrospektivna studija obuhvatila je 149 bolesnika s dTC-om 
i 159 uzoraka sumnjivih ln ili tkiva u ležištu štitnjače. Očekivano su razine sTg pokazale obrnutu korelaciju s razinom 
sTgAb (p <0,05), ali su vrijednosti fnA-Tg imale značajnu pozitivnu korelaciju s vrijednošću fnA-TgAb (p <0,05). našim 
rezultatima smo pokazali pozitivnu korelaciju vrijednosti sTg i fnA-Tg (p <0,05), ali ne i korelaciju između sTgAb i 
fnA-TgAb, kao niti sTgAb i fnA-Tg. Zaključujemo da vrijednosti sTgAb ne utječu na fnA-Tg te da je određivanje 
fnA-Tg visoko učinkovita metoda dijagnostike regionalnih metastaza dTC. Međutim, preporučuje se kombinirana upotre-
ba s citologijom za procjenu suspektnih čvorova vrata jer se citolologijom mogu istodobno otkriti metastaze i drugih tumora.
ključne riječi: ultrazvuk vrata, diferencirani karcinom štitnjače, aspiracijska biopsija tankom iglom (FNA), serumski tireo-
globulin (sTg), serumska anti-Tg protutijela (sTg-Ab), tireoglobulin (Tg) u aspiratu (FNA-Tg), anti-Tg protutijela u aspiratu 
(FNA-TgAb)
